PD-1 Inhibitors in the Advanced Esophageal Cancer

Overview

Journal Front Pharmacol

Date 2020 Jan 11

PMID 31920637

Citations 22

Authors

Ye Hong

Zhen-Yu Ding

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer (EC) is a lethal disease, and ranks 7th in incidence and 6th in mortality worldwide. Patients are treated with surgery and/or chemoradiotherapy for a curative intent, but for those with advanced diseases systemic chemotherapy and targeted therapy are the mainstay treatment with poor prognosis. For the patients with squamous cell carcinoma and those progressed after chemotherapy, treatment option is even fewer, and effective treatment modalities are urgently needed. Preclinical and clinical studies have found the PD-1/PD-L1 inhibitors activate T lymphocytes, inhibit cancer growth, and improve survival in cancer patients. Multiple PD-1/PD-L1 inhibitors have been approved for the management of a variety of cancers. Interestingly, a large of proportion of EC patients have tumors with PD-L1 expression and high tumor mutation burden. Trials have been performed to evaluate the efficacy and safety of the PD-1/PD-L1 inhibitors in EC patients. This review will summarize the current progress in this field, especially the toxicities associated with these agents.

Citing Articles

L3-SMI as a predictor of overall survival in oesophageal cancer patients receiving PD-1 inhibitors combined with chemotherapy.

Ying H, Chen Y, Hong Y, Ying K, Li S, Zhang Y Ann Med. 2024; 57(1):2440114.

PMID: 39665392 PMC: 11639058. DOI: 10.1080/07853890.2024.2440114.

Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma.

Sun M, Yang P, Wang W, Yu Y, Yang D, Ping Y Am J Cancer Res. 2024; 14(5):1981-1998.

PMID: 38859835 PMC: 11162652. DOI: 10.62347/XUWC6412.

A Correlation Evaluation Between the Peripheral Blood Index and the Prognosis of Advanced Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.

Shang H, Chen Y, Wang Q, Yang Y, Zhang J J Inflamm Res. 2024; 17:2009-2021.

PMID: 38566981 PMC: 10986412. DOI: 10.2147/JIR.S450669.

Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials.

Zafar S, Shehzadi R, Dawood H, Maqbool M, Sarfraz A, Sarfraz Z Ther Adv Med Oncol. 2024; 16:17588359231221339.

PMID: 38205080 PMC: 10777795. DOI: 10.1177/17588359231221339.

TNFSF15 and MIA Variant Associated with Immunotherapy and Prognostic Evaluation in Esophageal Cancer.

You J, Bian J, Chen J, Xia T, Deng A, Zhang M J Oncol. 2023; 2023:1248024.

PMID: 36936375 PMC: 10023233. DOI: 10.1155/2023/1248024.

References

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

Chedgy E, Black P . Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma. Urology. 2016; 89:8-9. DOI: 10.1016/j.urology.2015.12.003. View

Janjigian Y, Bendell J, Calvo E, Kim J, Ascierto P, Sharma P . CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018; 36(28):2836-2844. PMC: 6161834. DOI: 10.1200/JCO.2017.76.6212. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Thallinger C, Raderer M, Hejna M . Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011; 29(35):4709-14. DOI: 10.1200/JCO.2011.36.7599. View

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

Chen L, Han X . Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015; 125(9):3384-91. PMC: 4588282. DOI: 10.1172/JCI80011. View

10.

Wang J, Chang J, Yu H, Wu X, Wang H, Li W . A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. Cancer Chemother Pharmacol. 2013; 71(4):905-11. DOI: 10.1007/s00280-013-2081-5. View

11.

Hellmann M, Nathanson T, Rizvi H, Creelan B, Sanchez-Vega F, Ahuja A . Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):843-852.e4. PMC: 5953836. DOI: 10.1016/j.ccell.2018.03.018. View

12.

Abdo J, Agrawal D, Mittal S . Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther. 2016; 17(1):33-45. PMC: 5542819. DOI: 10.1080/14737140.2017.1260449. View

13.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D . Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018; 36(7):633-641. PMC: 6075848. DOI: 10.1200/JCO.2017.75.3384. View

14.

Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D . Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018; 24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. View

15.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

16.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

17.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

18.

Shi Y, Qin R, Wang Z, Dai G . Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther. 2013; 6:585-91. PMC: 3668960. DOI: 10.2147/OTT.S44406. View

19.

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M . Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin Oncol. 2017; 47(7):639-646. PMC: 5896687. DOI: 10.1093/jjco/hyx049. View

20.

Liu Y, Ren Z, Yuan L, Xu S, Yao Z, Qiao L . Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am J Cancer Res. 2016; 6(10):2345-2350. PMC: 5088297. View